Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial

Delafloxacin is a novel fluoroquinolone with activity against Gram-positive, Gram-negative, and atypical pathogens, including fluoroquinolone-nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA). The microbiological results of a phase 3 clinical trial in adults with community-acquired p...

Descripción completa

Detalles Bibliográficos
Autores principales: McCurdy, Sandra, Keedy, Kara, Lawrence, Laura, Nenninger, Ashley, Sheets, Amanda, Quintas, Megan, Cammarata, Sue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038307/
https://www.ncbi.nlm.nih.gov/pubmed/31844013
http://dx.doi.org/10.1128/AAC.01949-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038307/
https://www.ncbi.nlm.nih.gov/pubmed/31844013
http://dx.doi.org/10.1128/AAC.01949-19

Ejemplares similares